Please login to the form below

Letermovir

This page shows the latest Letermovir news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

The status for Prevymis ’ (letermovir) covers the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). ... to help ensure that appropriate

Latest news

CHMP backs MSD’s CMV infection treatment

Merck Sharp &Dohme (MSD) is closing on European approval for its infection treatment Prevymis (letermovir) after it received backing from the Committee for Medicinal Products for Human Use’s (CHMP) last ... The US Food and Drug Administration approved
Merck says drug for CMV in transplant patients hits targets

Merck says drug for CMV in transplant patients hits targets. Letermovir on course for fast-track 2017 filing and head start in prospective $350m market. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked
Merck & Co pays €110m upfront for AiCuris' CMV portfolio

Merck &Co pays 110m upfront for AiCuris' CMV portfolio. Lead candidate is orphan drug letermovir for transplant patients. ... Letermovir has been granted orphan drug status in the EU and the US, and has also been earmarked for fast-track review by the FDA

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Pharma deals during October 2012

Letermovir has orphan drug status in the EU and the US, where it has also been granted fast track designation. ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase IIb) and antiviral portfolio for CMV.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director – Global Healthcare PR: Salary TBC

Senior Account Executive – Medical Communications: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Editorial Director – Medical Education: Neg

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Experienced Editor, London, Medical Communications: Competitive package

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Director: Negotiable

Scientific Team Lead: Competitive Salary

Director Healthcare PR Communications: Salary TBC

Associate Medical Director: Highly Competitive

Healthcare PR Director: £100, 000 – £120, 000 benefits

Associate Medical Director: Salary TBC

Account Director - Digital: Great salary and benefits

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Scientific Director: Highly Competitive Salary &Benefits

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Director – Head of Public Affairs: Neg

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Manager, Healthcare Advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...
Tackling a formidable foe: Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...